October 03, 2024 – ETCTN
CTEP is accepting LOIs to conduct clinical studies using Camonsertib, an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor (ATRi), which is being developed by CTEP as an anticancer agent in collaboration with…
that provides shared resources and a collaborative environment for over 1,100 cancer researchers at 7 Harvard institutions. Learn more about DF/HCC here
Clinical Investigator Support and Trial Search Tool